Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
Go back to Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models| GALMED PHARMACEUTIC (NASDAQ: GLMD) | Delayed: 4.63 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.63 | 52 Week High | $9.70 | |||
| Open | $4.63 | 52 Week Low | $2.78 | |||
| Day High | $4.63 | P/E | N/A | |||
| Day Low | $4.63 | EPS | $0.00 | |||
| Volume | 3,818 | |||||
